CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced that patient dosing is underway in the iNSITE 2 trial, a global, phase 2, two-stage clinical trial of BIND-014 in patients with four tumor histologies. These diseases (cholangiocarcinoma [bile duct cancer], advanced cervical cancer, advanced bladder cancer, and advanced squamous cancer of the head and neck) each affect fewer than 200,000 patients in the U.S., making investigational drugs for these diseases candidates for orphan drug designation by the U.S. Food and Drug Administration. Stage 1 data readout for the iNSITE 2 trial is expected in the first half of 2016.
“The dosing of the first patient in the iNSITE 2 trial further expands the clinical development opportunities of BIND-014,” said Hagop Youssoufian, M.Sc., M.D., chief medical officer at BIND Therapeutics. “It also represents a new milestone for the first targeted nanoparticle to enter the clinic by utilizing a rigorous biomarker program that can become a useful aid for more reliable patient selection in the future. The orphan tumor types that we have chosen for iNSITE 2 are all cancers with high unmet need and limited treatment options, representing potential opportunities for rapid development. Our choice was also guided by the activity seen with BIND-014 in our phase 1 trial and the historical role of docetaxel in treating these tumors.”
The open-label, phase 2, multi-center two-stage iNSITE 2 clinical trial is designed to determine the activity, safety and tolerability of BIND-014 and will enroll up to 160 patients. In addition, an imaging and biomarker program that can potentially inform the future clinical utility of BIND-014 is also planned. Additional information on this study can be found at: https://www.clinicaltrials.gov.
About BIND Therapeutics
BIND Therapeutics is a
clinical-stage nanomedicine company developing a pipeline of Accurins™,
its novel targeted therapeutics designed to increase the concentration
and duration of therapeutic payloads at disease sites while reducing
exposure to healthy tissue. BIND is leveraging its Medicinal
Nanoengineering® platform to develop a pipeline of Accurins
targeting hematological and solid tumors and has a number of strategic
collaborations with biopharmaceutical companies to develop Accurins in
areas of high unmet need. BIND's lead drug candidate, BIND-014, is a
prostate-specific membrane antigen (PSMA) -targeted Accurin that
contains docetaxel, a clinically-validated and widely-used cancer
chemotherapy drug. BIND-014 is currently in development for the
treatment of non-small cell lung cancer, or NSCLC, in patients with KRAS
mutations or squamous histology. BIND has also initiated clinical trials
with BIND-014 in cervical, bladder, head and neck and cholangio cancers.
In addition, BIND is advancing BIND-510, its second PSMA-targeted
Accurin drug candidate containing vincristine, a potent microtubule
inhibitor with dose limiting peripheral neuropathy in its conventional
form, through important preclinical studies to position it for an
Investigational New Drug application filing with the U.S. Food and Drug
Administration in 2016. Lastly, BIND is developing Accurins designed to
inhibit PLK1 and KSP, both of which BIND believes are promising
anti-mitotic targets that have been limited in the clinic due to
myelotoxicity at or below therapeutic doses.
BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck & Co., or Merck (known as Merck Sharp & Dohme outside the United States and Canada) and Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals) to develop Accurins based on their proprietary therapeutic payloads and/or targeting ligands. BIND’s collaboration with AstraZeneca has resulted in FDA clearance to begin clinical trials with the Aurora B Kinase inhibitor Accurin AZD2811, which is expected to become the second Accurin candidate to enter clinical development.
For more information, please visit the Company's web site at www.bindtherapeutics.com.
Forward-Looking Statements Disclaimer
This press release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained in
this press release that do not relate to matters of historical fact
should be considered forward-looking statements, including statements
regarding the iNSITE 2 clinical trial of BIND-014, including without
limitation the anticipated timing of our announcement of clinical trial
data and the trial’s expansion of the clinical development opportunities
for BIND-014; the potential for orphan drug designation for
investigational drugs for the diseases being studied in the iNSITE 2
trial and potential opportunities for rapid development of potential
treatments of these diseases; an imaging and biomarker program related
to BIND-014’s future clinical utility; Accurins, and developing a
pipeline of Accurins; BIND-510, including without limitation, statements
regarding our plan for an Investigational New Drug filing in 2016; our
collaboration agreements with Pfizer, Merck, AstraZeneca, F. Hoffmann-La
Roche Ltd., and Macrophage; and AZD2811 entering clinical development.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the Company has incurred significant losses since its inception and expects to incur losses for the foreseeable future; the Company's need for additional funding, which may not be available; raising additional capital may cause dilution to its stockholders, restrict its operations or require it to relinquish rights to its technologies or drug candidates; the Company's limited operating history; the terms of the Company's credit facility place restrictions on its operating and financial flexibility; failure to use and expand its medicinal nanoengineering platform to build a pipeline of drug candidates and develop marketable drugs; the early stage of the Company's development efforts with only one drug candidate in clinical development; failure of the Company or its collaborators to successfully develop and commercialize drug candidates; clinical drug development involves a lengthy and expensive process, with an uncertain outcome; delays or difficulties in the enrollment of patients in clinical trials; serious adverse or unacceptable side effects or limited efficacy observed during the development of the Company's drug candidates; inability to maintain any of the Company's collaborations, or the failure of these collaborations; the Company's reliance on third parties to conduct its clinical trials and manufacture its drug candidates; the Company's inability to obtain required regulatory approvals; any conclusion by the FDA that BIND-014 does not satisfy the requirements for approval under the Section 505(b)(2) regulatory approval pathway; the fact that a fast track or breakthrough therapy designation by the FDA for the Company's drug candidates may not actually lead to a faster development or regulatory review or approval process; the inability to obtain orphan drug exclusivity for drug candidates; failure to obtain marketing approval in international jurisdictions; any post-marketing restrictions or withdrawals from the market; effects of recently enacted and future legislation; failure to comply with environmental, health and safety laws and regulations; failure to achieve market acceptance by physicians, patients, or third-party payors; failure to establish effective sales, marketing and distribution capabilities or enter into agreements with third parties with such capabilities; effects of substantial competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to retain key executives and attract, retain and motivate qualified personnel; difficulties in managing the Company's growth; risks associated with operating internationally, including the possibility of sanctions with respect to our operations in Russia; the possibility of system failures or security breaches; failure to obtain and maintain patent protection for or otherwise protect our technology and products; effects of patent or other intellectual property lawsuits; the price of our common stock may be volatile and fluctuate substantially; increased costs as a result of operating as a public company; and any securities class action litigation. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on August 6, 2015, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
